Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121611) titled 'Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC' on April 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Completely Resected Stage IA1-IA2 with High-risk Factors and Stage IA3 EGFR-Mutated NSCLC
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2026-04-01
Target Sample Size: Firmonertinib Group:535;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=316332
Published by HT Digital Content Services with permission from He...